NCT06236633 (AMIREMBOL_2) is a NA clinical trial of Ischemic preconditioning in Cancer, Rectal, sponsored by Centre Hospitalier Universitaire de Nīmes.

Who is sponsoring NCT06236633?

NCT06236633 is sponsored by Centre Hospitalier Universitaire de Nīmes.

What drugs are being tested in NCT06236633?

Interventions in NCT06236633: Ischemic preconditioning, Arteriogram.

What condition does NCT06236633 study?

NCT06236633 studies Cancer, Rectal.

Is NCT06236633 still recruiting?

NCT06236633 is currently recruiting now. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT06236633: AMIREMBOL_2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety & Efficacy of Ischemic Preconditioning by Embolization of the Inferior Mesenteric Artery in Surgery for Tumors of Lower and Middle Rectum

Recruiting now NA Last updated 4 December 2025

What this trial tests

NA trial testing Ischemic preconditioning in Cancer, Rectal in 30 participants. Currently enrolling.

Timeline

2 August 2024

Primary endpoint
1 August 2026

1 August 2027

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	2 August 2024
Primary completion	1 August 2026
Estimated completion	1 August 2027
Sites	3 locations across France

Drugs / interventions tested

Ischemic preconditioning — full drug profile →
Arteriogram

Conditions studied

Cancer, Rectal — all drugs for Cancer, Rectal →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

Adults 18 to 90, any sex, with Cancer, Rectal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will investigate the safety of inferior mesenteric artery embolization prior to rectal surgery, according to IDEAL recommendations (Lancet 2009). It aims to assess the safety of endovascular embolization of the inferior mesenteric artery prior to surgery in patients with rectal tumors, and estimate the potential benefits in terms of time to surgery and the occurrence of post-operative fistulas.The study will also assess the impact of subacute ischemia induced by IMA embolization on colonic vasculature remodeling, colonic ischemic suffering, altered hemostasis and initiation of neo-angiogenesis through blood sampling kinetics.The hypothesis is that ischemic preconditioning by inferior mesenteric artery embolization prior to rectal cancer resection surgery is safe and will result in a decrease in acute relative colon ischemia and a reduction in the rate of fistulas and post-surgical complications. Indeed, we believe that the beneficial effects of the ischemic preconditioning of IMA will be due to better blood perfusion of the colon at 3 weeks, which is apparently linked to remodeling and/or the development of collateral vascularization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ischemic preconditioning

Trials testing the same drug.

NCT06825143 — Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury · EARLY_PHASE1 · not yet recruiting
NCT07497958 — Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy · NA · not yet recruiting
NCT04887610 — Factors That Influence Blood Vessel Regulation During Exercise in Humans · NA · completed
NCT03238391 — Ischemic Preconditioning for Prevention of Contrast Nephropathy in The Emergency Department · NA · unknown
NCT03136458 — Efficacy of Remote Ischemic Preconditioning as Non Pharmacologic Strategy to Prevent Contrast Induced Nephropathy (PAIR) · NA · withdrawn

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06236633 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06236633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing